Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Spain ,Italy ,China ,Ivrea ,Piemonte ,Zhejiang ,Zaragoza ,Baja California ,Mexico ,Haiyan ,Yunnan ,Millburn ,Japan ,Sasayama ,Hyogo ,America ,Theodore Laetsch ,Prnewswire Novartis ,Michael Meo ,Marlena Abdinoor ,Parag Mahanti ,Sloan Simpson ,Jonathan Graham ,Tina Deignan ,Elsevier Inc ,Instagram ,Novartis ,Developmental Therapeutics Program ,Facebook ,Drug Administration ,Linkedin ,Exchange Commission ,Therapeutic Area Head ,Radioligand Therapy ,Prescribing Information ,Metab Clin North ,Survival Outcomes ,Patients With Neuroendocrine Tumors ,Related Cancer ,Gastroenteropancreatic Neuroendocrine ,Evaluate Safety ,Adolescent Patients With ,Accessed March ,Full Prescribing ,Product Characteristics ,Clinical Radiation ,